Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant received at least two Ozurdex® implants in the study eye to treat visual impairment due to DME
First Ozurdex® implant injection occurred after 1 January 2015
Participant was followed-up at the site for at least 12 months after the first Ozurdex® implant in the study eye
You may not be if
\- Participant received Ozurdex® implants as part or during a clinical study
Clareo Health | Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
